Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
CC-885 (CC885) is a novel and potent cereblon (CRBN) modulator with potent antitumour activity, it acts by the degradation of GSPT1 and was demonstrated to mediate antitumor effects through the recruitment and degradation of G1 to S phase transition 1 protein (GSPT1). GSPT1 (also named eRF3a) is a translation termination factor that binds eukaryotic translation termination factor 1 (eFR1) to mediate stop codon recognition and nascent protein release from the ribosome.
Targets |
CRBN
|
|
---|---|---|
ln Vitro |
CC-885 is applied at different concentrations to human peripheral blood mononuclear cells (PBMC), human liver epithelial cell line (THLE-2) and acute myeloblatlic leukemia (AML) cell lines, with IC50s of 10×-6-1 μM. With IC50s>10 μM, CC-885 has a greater effect on cell proliferation in AML cell lines, THLE-2, and human PBMC than Lenalidomide and Pomalidomide.In order to determine whether the cytotoxic effects of CC-885 are caused by the cereblon-dependent degradation of GSPT1, a GSPT1 mutant that maintains its normal function but does not exhibit CC-885-dependent cereblon binding is employed to differentiate GSPT1's function from that of other substrates. In 293T HEK cells that consistently express CC-885-sensitive or -resistant GSPT1 variants, CC-885 is tested. While overexpressing a CC-885-sensitive variant, GSPT1Δ(1-138), only partially protects against the CC-885-induced anti-proliferation, overexpressing a resistant variant, GSPT1Δ(1–138)/(G575N), completely abrogates the effect. AML cell lines yield comparable outcomes[1].
|
|
ln Vivo |
|
|
Cell Assay |
The growth medium-cultured human cancer cell lines are seeded into black 384-well plates with DMSO or test compounds like CC-885 (10×-6-1 μM). Every cell line's seeding density is carefully calibrated to facilitate cell growth within the linear range over the course of a three-day culture period. Black 96-well plates containing DMSO or test compounds like CC-885 are seeded with 5,000–10,000 cells per well in 200 μl complete culture media to test the compound effect on cell proliferation in acute myeloid leukemia (AML) cell lines. Cell proliferation is measured using the CellTiter-Glo (CTG) Luminescent Cell Viability Assay after 48 or 72 hours[1].
|
|
References |
Molecular Formula |
C22H21CLN4O4
|
---|---|
Molecular Weight |
440.879544019699
|
Exact Mass |
440.13
|
Elemental Analysis |
C, 59.93; H, 4.80; Cl, 8.04; N, 12.71; O, 14.52
|
CAS # |
1010100-07-8
|
Appearance |
Off white to light purple solid powder
|
SMILES |
O=C(NCC1=CC2=C(C(N(C(CC3)C(NC3=O)=O)C2)=O)C=C1)NC4=CC=C(C)C(Cl)=C4
|
InChi Key |
DOEVCIHTTTYVCC-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C22H21ClN4O4/c1-12-2-4-15(9-17(12)23)25-22(31)24-10-13-3-5-16-14(8-13)11-27(21(16)30)18-6-7-19(28)26-20(18)29/h2-5,8-9,18H,6-7,10-11H2,1H3,(H2,24,25,31)(H,26,28,29)
|
Chemical Name |
N-(3-chloro-4-methylphenyl)-N'-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1-oxo-1H-isoindol-5-yl]methyl]-urea
|
Synonyms |
CC-885; CC 885; CC885.
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : 40~67.5 mg/mL ( 90.72~153.10 mM )
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 2.25 mg/mL (5.10 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.25 mg/mL (5.10 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2682 mL | 11.3410 mL | 22.6819 mL | |
5 mM | 0.4536 mL | 2.2682 mL | 4.5364 mL | |
10 mM | 0.2268 mL | 1.1341 mL | 2.2682 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.